Golden State Equity Partners’s Halozyme HALO Stock Holding History

Golden State Equity Partners’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10	Closed	-$646	–	917
2026 Q1	$646	Buy	+10	New	+$705	﹤0.01%	1846

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Golden State Equity Partners's HALO Position: Q2 2026 in Review

Golden State Equity Partners sold out of Halozyme (HALO) in Q2 2026, closing a stake of 10 shares — an estimated $646 sold.

Golden State Equity Partners first reported a position in HALO in Q1 2026 and held it in 1 quarter. The position peaked at $646 in Q1 2026. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Golden State Equity Partners reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 10 Halozyme shares in Q2 2026, an estimated $646.
Golden State Equity Partners first reported a position in Halozyme in Q1 2026 and held it in 1 quarter.
Golden State Equity Partners's Halozyme position peaked at $646 in Q1 2026.
671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.